These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 30830654)

  • 1. Pentoxifylline for the prevention of contrast-induced nephropathy in diabetic patients undergoing angioplasty: a randomized controlled trial.
    Aslanabadi N; Afsar Gharebagh R; Moharramzadeh S; Entezari-Maleki T
    Int Urol Nephrol; 2019 Apr; 51(4):699-705. PubMed ID: 30830654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of pentoxifylline in prevention of contrast-induced nephropathy in angioplasty patients.
    Firouzi A; Eshraghi A; Shakerian F; Sanati HR; Salehi N; Zahedmehr A; Kiani R; Madani M; Pedarzadeh A
    Int Urol Nephrol; 2012 Aug; 44(4):1145-9. PubMed ID: 21898040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The preventive effect of pentoxifylline on contrast-induced nephropathy: a randomized clinical trial.
    Yavari V; Ostovan MA; Kojuri J; Afshariani R; Hamidian Jahromi A; Roozbeh J; Pakfetrat M
    Int Urol Nephrol; 2014 Jan; 46(1):41-6. PubMed ID: 23572413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High Loading Dose of Atorvastatin for the Prevention of Serum Creatinine and Cystatin C-Based Contrast-Induced Nephropathy Following Percutaneous Coronary Intervention.
    Fu N; Liang M; Yang S
    Angiology; 2018 Sep; 69(8):692-699. PubMed ID: 29343076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of contrast-induced nephropathy with single bolus erythropoietin in patients with diabetic kidney disease: A randomized controlled trial.
    Shema-Didi L; Kristal B; Eizenberg S; Marzuq N; Sussan M; Feldman-Idov Y; Ofir P; Atar S
    Nephrology (Carlton); 2016 Apr; 21(4):295-300. PubMed ID: 26370061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 20-Hour preprocedural hydration is not superior to 5-hour preprocedural hydration in the prevention of contrast-induced increases in serum creatinine and cystatin C.
    Torigoe K; Tamura A; Watanabe T; Kadota J
    Int J Cardiol; 2013 Sep; 167(5):2200-3. PubMed ID: 22717305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved estimation of glomerular filtration rate by serum cystatin C in preventing contrast induced nephropathy by N-acetylcysteine or zinc--preliminary results.
    Kimmel M; Butscheid M; Brenner S; Kuhlmann U; Klotz U; Alscher DM
    Nephrol Dial Transplant; 2008 Apr; 23(4):1241-5. PubMed ID: 18174269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of N-acetylcysteine on cystatin C-based renal function after elective coronary angiography (ENABLE Study): a prospective, randomized trial.
    Kim BJ; Sung KC; Kim BS; Kang JH; Lee KB; Kim H; Lee MH
    Int J Cardiol; 2010 Feb; 138(3):239-45. PubMed ID: 18793808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pentoxifylline for the prevention of contrast-induced nephropathy: systematic review and meta-analysis of randomised controlled trials.
    Wei L; Zhang W; Yang Y; Li D
    BMJ Open; 2021 Apr; 11(4):e043436. PubMed ID: 33945499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated serum cystatin C level is an independent predictor of contrast-induced nephropathy and adverse outcomes in patients with peripheral artery disease undergoing endovascular therapy.
    Kim GS; Ko YG; Shin DH; Kim JS; Kim BK; Choi D; Hong MK; Jang Y
    J Vasc Surg; 2015 May; 61(5):1223-30. PubMed ID: 25595408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pentoxifylline and prevention of contrast-induced nephropathy: Is it efficient in patients with myocardial infarction undergoing coronary angioplasty?
    Eshraghi A; Naranji-Sani R; Pourzand H; Vojdanparast M; Morovatfar N; Ramezani J; Khamene-Bagheri R; Nezafati P
    ARYA Atheroscler; 2016 Sep; 12(5):238-242. PubMed ID: 28458699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effectiveness of N-Acetylcysteine in preventing contrast-induced nephropathy in patients undergoing contrast-enhanced computed tomography: a meta-analysis of randomized controlled trials.
    Wu MY; Hsiang HF; Wong CS; Yao MS; Li YW; Hsiang CY; Bai CH; Hsu YH; Lin YF; Tam KW
    Int Urol Nephrol; 2013 Oct; 45(5):1309-18. PubMed ID: 23283594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preprocedure and Postprocedure Predictive Values of Serum β2-Microglobulin for Contrast-Induced Nephropathy in Patients Undergoing Coronary Computed Tomography Angiography: A Comparison With Creatinine-Based Parameters and Cystatin C.
    Li S; Zheng Z; Tang X; Peng L; Luo Y; Dong R; Zhao Y; Liu J
    J Comput Assist Tomogr; 2015; 39(6):969-74. PubMed ID: 26248154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of contrast-induced nephropathy by N-acetylcysteine in critically ill patients: different definitions, different results.
    Chousterman BG; Bouadma L; Moutereau S; Loric S; Alvarez-Gonzalez A; Mekontso-Dessap A; Laissy JP; Rahmouni A; Katsahian S; Brochard L; Schortgen F
    J Crit Care; 2013 Oct; 28(5):701-9. PubMed ID: 23683568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized controlled trial comparing hydration therapy to additional hemodialysis or N-acetylcysteine for the prevention of contrast medium-induced nephropathy: the Dialysis-versus-Diuresis (DVD) Trial.
    Reinecke H; Fobker M; Wellmann J; Becke B; Fleiter J; Heitmeyer C; Breithardt G; Hense HW; Schaefer RM
    Clin Res Cardiol; 2007 Mar; 96(3):130-9. PubMed ID: 17180572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of high loading dose of atorvastatin in diabetic patients with renal dysfunction undergoing elective percutaneous coronary intervention: a randomized controlled trial.
    Shehata M; Hamza M
    Cardiovasc Ther; 2015 Apr; 33(2):35-41. PubMed ID: 25677920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Could neutrophil-gelatinase-associated lipocalin and cystatin C predict the development of contrast-induced nephropathy after percutaneous coronary interventions in patients with stable angina and normal serum creatinine values?
    Bachorzewska-Gajewska H; Malyszko J; Sitniewska E; Malyszko JS; Pawlak K; Mysliwiec M; Lawnicki S; Szmitkowski M; Dobrzycki S
    Kidney Blood Press Res; 2007; 30(6):408-15. PubMed ID: 17901710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preventive effects of anisodamine against contrast-induced nephropathy in type 2 diabetics with renal insufficiency undergoing coronary angiography or angioplasty.
    Geng W; Fu XH; Gu XS; Wang YB; Wang XC; Li W; Jiang YF; Hao GZ; Fan WZ; Xue L
    Chin Med J (Engl); 2012 Oct; 125(19):3368-72. PubMed ID: 23044290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes of contrast-induced nephropathy in patients undergoing percutaneous coronary intervention: a prospective, multicenter, randomized study to analyze the effect of hydration and acetylcysteine.
    Chen SL; Zhang J; Yei F; Zhu Z; Liu Z; Lin S; Chu J; Yan J; Zhang R; Kwan TW
    Int J Cardiol; 2008 Jun; 126(3):407-13. PubMed ID: 17651830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Probucol for the prevention of cystatin C-based contrast-induced acute kidney injury following primary or urgent angioplasty: a randomized, controlled trial.
    Yin L; Li G; Liu T; Yuan R; Zheng X; Xu G; Xu Y; Che J; Liu X; Ma X; Li F; Liu E; Chen X; Wu L; Fan Z; Ruan Y; He M; Li Y
    Int J Cardiol; 2013 Jul; 167(2):426-9. PubMed ID: 22305809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.